Acute Respiratory Distress Syndrome – ARDS is under clinical development by Orbsen Therapeutics and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData, Phase II drugs for Primary Sclerosing Cholangitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Acute Respiratory Distress Syndrome – ARDS LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Acute Respiratory Distress Syndrome – ARDS overview

Stem cell therapy is under development for the treatment of acute respiratory distress syndrome, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), systemic sepsis, primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), rheumatoid Arthritis, lupus Nephritis and crohn's Disease.. It is CD362 enriched human umbilical cord-derived mesenchymal stromal cells  and is administered by intravenous and intravenous drip. The stem cell therapy is regenerative medicine therapy consisting of pure and defined stromal cells isolated from human tissue.

Orbsen Therapeutics overview

Orbsen Therapeutics is a regenerative medicine company focused on developing stromal cell treatments to address some of most challenging diseases. Orbsen Therapeutics is headquartered in Galway, Ireland.

For a complete picture of Acute Respiratory Distress Syndrome – ARDS’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.